← Human Trials & Peer-Reviewed Studies
Temporal Patterns of Glucagon and Its Relationships with Glucose and Insulin following Ingestion of Different Classes of Macronutrients
Plain-language guide to PMID 35057557 (2022): crossover randomized controlled trial study of Glucagon.
Key Facts
- PMID
- 35057557
- Journal
- Nutrients
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Göbl C et al. (7 authors)
- DOI
- 10.3390/nu14020376
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Glucagon, published as a randomized controlled trial.
The researchers aimed to investigate the associations between plasma glucagon, glucose, and insulin after ingestion of single macronutrients or mixed-meal.
Why It Was Studied
Glucagon secretion and inhibition should be mainly determined by glucose and insulin levels, but the relative relevance of each factor is not clarified, especially following ingestion of different macronutrients.
Who Took Part
The age groups tagged for this paper are middle-aged adults, both men and women.
Thirty-six participants underwent four metabolic tests, based on administration of glucose, protein, fat, or mixed-meal.
The researchers analyzed relationships between time samples of glucagon, glucose, and insulin in each individual, as well as between suprabasal area-under-the-curve of the same variables (ΔAUCGLUCA, ΔAUCGLU, ΔAUCINS) over the whole participants' cohort.
How the Study Was Run
The design is described as randomized and crossover.
The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.
In the crossover set-up each of the participants took both Glucagon and the comparison in turn, acting as their own control.
Glucagon, glucose, insulin, and C-peptide were measured at fasting and for 300 min following food ingestion.
What Was Measured
Glucagon secretion and inhibition should be mainly determined by glucose and insulin levels, but the relative relevance of each factor is not clarified, especially following ingestion of different macronutrients.
PubMed files the paper under topics including Area Under Curve, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Fasting, Glucagon and Glucose Tolerance Test.
Author keywords: glucagon determinants, glucagon shape, glucose homeostasis, individual associations, lipids and mathematical modeling.
What This Means in Plain Language
The paper is a randomized and crossover study of Glucagon.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2022 (Nutrients), a journal based in Switzerland.
More context: the Glucagon compound page, all human trials.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.